TEVA PHARMACEUTICALS USA, INC.
North Wales, PA US
|TEVA PHARMACEUTICALS USA, INC. Patent applications|
|Patent application number||Title||Published|
|20150058039||METHOD, SYSTEM AND PROGRAM FOR IMPROVED HEALTH CARE - A platform accessible by a user from a web browser/HMO's electronic medical record (EMR) for providing the user with information regarding a patient's drug regimen as well as generating alerts concerning potential adverse effects to a patient from taking a cluster including a plurality of pharmaceutical preparations and various food supplements/herbals may be in data communication with and configured to obtain information from at least two databases and at least one tool for processing the cluster of pharmaceutical preparations in accordance with the information to generate the alerts to the user.||02-26-2015|
|20140050784||PHARMACEUTICAL COMPOSITIONS OF MEMANTINE - The present invention relates to oral dosage forms comprising Memantine or a pharmaceutically acceptable salt thereof, pharmaceutical formulations comprising the oral dosage forms, and methods for treating mild, moderate or severe Alzheimer's dementia, or neuropathic pain comprising the oral dosage forms and formulations.||02-20-2014|
|20130203674||PROCESS FOR PRODUCTION OF BIVALIRUDIN - The invention relates to methods for the preparation of high purity Bivalirudin. The polypeptide is prepared in a high purity of at least 98.5% (by HPLC), wherein the total impurities amount to less than 1.5%, comprising not more than 0.5% [Asp||08-08-2013|
|20130196920||PROCESS FOR PRODUCTION OF BIVALIRUDIN - The invention relates to methods for the preparation of high purity Bivalirudin. The polypeptide is prepared in a high purity of at least 98.5% (by HPLC), wherein the total impurities amount to less than 1.5%, comprising not more than 0.5% [Asp||08-01-2013|
|20130196919||PROCESS FOR PRODUCTION OF BIVALIRUDIN - The invention relates to methods for the preparation of high purity Bivalirudin. The polypeptide is prepared in a high purity of at least 98.5% (by HPLC), wherein the total impurities amount to less than 1.5%, comprising not more than 0.5% [Asp||08-01-2013|
|20120238555||Pharmaceutical composition containing irbesartan - This invention relates to pharmaceutical compositions containing irbesartan, providing oral formulations with a high relative amount or concentration of irbesartan. In one embodiment, the present invention provides an oral formulation of irbesartan containing greater than 70% w/w irbesartan. In another embodiment, the invention provides an oral formulation of irbesartan which exhibits a dissolution profile according to which greater than about 85% of the Irbesartan is dissolved within about 30 minutes using USP apparatus 2, placing the tablet in 1000 mL of 0.1N hydrochloric acid at 37° C. with paddle speed of 50 rpm. The formulation can optionally contain at least one additional active ingredient.||09-20-2012|
|20120220663||SOLID FORMS OF ALISKIREN HEMIFUMARATE AND PROCESSES FOR PREPARATION THEREOF - The present invention provides polymorphic forms of aliskiren hemifumarate, and processes for preparation thereof and for the preparation of the amorphous form of aliskiren hemifumarate. The present invention also provides pharmaceutical compositions comprising the aliskiren hemifumarate crystalline forms T1, T3 or T4, T5, T6, T7, T8 and at least one pharmaceutically acceptable excipient, and the use of these pharmaceutical compositions in the treatment of hypertension.||08-30-2012|
|20100076195||PURIFICATION OF MONTELUKAST - The present invention provides methods of purifying montelukast, a new isolated impurity of montelukast, method for its isolation, and method of using montelukast impurity as a reference marker and a reference standard.||03-25-2010|
|20090240054||Rosuvastatin calcium with a low salt content - Provided is rosuvastatin calcium with a low salt by product content and processes for preparing such rosuvastatin calcium.||09-24-2009|
|20090188305||Reference standard for characterization of rosuvastatin - Provided are rosuvastatin degradation products and their use as a reference standard (including reference marker) for analysis of rosuvastatin.||07-30-2009|
|20090082398||CRYSTALLINE FORMS OF FEXOFENADINE HYDROCHLORIDE AND PROCESSES FOR THEIR PREPARATION - Provided are crystalline forms of fexofenadine hydrochloride and processes for their preparation.||03-26-2009|
Patent applications by TEVA PHARMACEUTICALS USA, INC.